z-logo
open-access-imgOpen Access
Stopping Anti-TNF in CD Remitters: Cons
Author(s) -
Kobayashi Taku
Publication year - 2021
Publication title -
inflammatory intestinal diseases
Language(s) - English
Resource type - Journals
eISSN - 2296-9365
pISSN - 2296-9403
DOI - 10.1159/000517961
Subject(s) - review article
Crohn’s disease may cause a life-long disease burden in many aspects due to its progressive nature. A large proportion of refractory patients have been benefiting from scheduled maintenance anti-TNF treatment; therefore, strategy to stop anti-TNF agents in Crohn’s disease is not widely conducted. There have been observational studies demonstrating that approximately half of the patients relapse within a year after discontinuation. Several factors have been suggested as potential predictors for relapse; however, a consensus has not been reached so far. Although most relapse can be rescued by the re-treatment with the same anti-TNF agent, a proportion of patients may result in progressive bowel damage and the need for surgery. Therefore, an attempt to stop anti-TNF is not recommended without careful discussion, even if they are in long-term remission.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom